Exagen Inc. filings document formal disclosures for an autoimmune diagnostics company focused on AVISE-branded testing products. Current reports on Form 8-K furnish operating results and financial condition updates, including revenue, AVISE CTD test volume, average selling price, gross margin, operating expenses, net loss, adjusted EBITDA and cash measures.
Proxy materials cover annual meeting matters, board governance, committee membership, director elections, executive compensation and equity-award disclosures. Other 8-K filings record governance changes such as director departures, board size adjustments and committee assignments within Exagen’s public-company reporting framework.
EXAGEN INC. ten percent owner Chernett Jorey purchased 14,000 shares of common stock on October 19, 2026, at a weighted average price of $7.46 per share, rounded to the nearest cent. The shares were purchased in multiple transactions priced from $7.44 to $7.48, inclusive. Jorey reported direct holdings of 2,618,540 shares following the purchase. No Rule 10b5-1 plan is reported.
Exagen Inc. President and CEO John Aballi reported a sale of 34,294 common shares on October 16, 2026, at $7.8670 per share. The sale funded tax withholding tied to restricted stock unit vesting and settlement, as required by the issuer, and was not discretionary. Afterward, he reported 805,540 shares held directly; the report also lists 40,401 shares held indirectly by his spouse. No Rule 10b5-1 plan is reported.
Exagen Inc. (XGN) reports that Chernett Jorey, a ten percent owner, directly held 2,604,540 common shares as of October 16, 2026.
EXAGEN INC. (XGN) reported that its Chief Financial Officer, Jeffrey G. Black, had mixed equity activity on September 1, 2026. He sold 20,614 shares of common stock at an average price of $7.2175 per share to cover tax withholding on vesting Restricted Stock Units, a transaction mandated by the company. On the same date, he acquired 1,571 shares of common stock at $3.0175 per share through the company’s Employee Stock Purchase Plan.
EXAGEN INC. (XGN) director Bruce C. Robertson reported a grant of 37,500 stock options on June 9, 2026. The options have an exercise price of $4.31 per share, are exercisable for 37,500 shares of common stock, and expire on June 8, 2036. The award becomes fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to his continued board service. An earlier Form 4 had overstated his post-grant holdings; this amendment clarifies that he beneficially owns 37,500 stock options in total.
EXAGEN INC. (XGN) director Bruce C. Robertson reported an award of a stock option covering 37,500 shares of common stock at an exercise price of $4.31 per share on June 9, 2026. The option expires on June 8, 2036 and becomes fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual stockholders’ meeting, contingent on his continued board service. Following this grant, he holds options on 55,500 shares directly.
EXAGEN INC. (XGN) reported that director Paul Kim received a grant of stock options. On 2026-06-09, he was awarded 37,500 stock options to purchase common stock at an exercise price of $4.31 per share, expiring on 2036-06-08. These options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to his continued board service. Following this grant, Kim holds 46,500 options directly.
Exagen Inc. reported Q2 2026 revenue of $19.9M, up from $17.2M a year earlier, driven mainly by its AVISE® CTD autoimmune diagnostic test, which contributed about 89% of quarterly revenue. Gross profit rose to $12.2M, while the operating loss narrowed to $1.7M.
Net loss improved to $3.2M (basic and diluted net loss per share of $0.13) versus $4.4M in Q2 2025. For the first six months, operating cash outflow decreased to $6.4M, leaving cash and cash equivalents of $24.6M against total borrowings of about $22.8M. Management expects existing capital to fund operations for at least twelve months, while noting that additional financing may be required to support longer-term growth initiatives and ongoing development of new AVISE®-branded tests.
Exagen Inc. reported second quarter 2026 results with record total revenue of $19.9 million, up 16% from the second quarter of 2025, and increased full-year 2026 revenue guidance to $72–$75 million from $70–$73 million.
For the quarter ended June 30, 2026, revenue was $19,941 thousand with gross margin of 61.3%. Net loss narrowed to $3,196 thousand, nearly a 30% improvement from $4,439 thousand a year earlier, and adjusted EBITDA loss improved to $114 thousand, or about $0.1 million, from $1,721 thousand.
Exagen reported record AVISE CTD test volume, a trailing-twelve-month ASP of $446 per test, up $18 or 4% year over year, and ended the quarter with approximately $25 million in cash and cash equivalents. Management highlighted progress toward sustainable profitability while continuing to invest in clinical evidence, pipeline innovation and AI-powered tools that support rheumatology workflows.
EXAGEN INC. director Scott D. Kahn reported receiving a stock option grant covering 37,500 shares of common stock. The option has an exercise price of $4.31 per share and expires on June 8, 2036.
According to the terms, all 37,500 option shares become fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as Kahn continues to serve on the board through that date. After this grant, he directly holds options on 46,500 shares.